- Home
- PTGX vs TSLX Comparison
PTGX vs TSLX Comparison
Compare PTGX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- TSLX
- Stock Information
- Founded
- PTGX 2006
- TSLX 2010
- Country
- PTGX United States
- TSLX United States
- Employees
- PTGX N/A
- TSLX N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- PTGX Health Care
- TSLX Finance
- Exchange
- PTGX Nasdaq
- TSLX Nasdaq
- Market Cap
- PTGX 2.8B
- TSLX 1.9B
- IPO Year
- PTGX 2016
- TSLX 2014
- Fundamental
- Price
- PTGX $47.91
- TSLX $20.40
- Analyst Decision
- PTGX Strong Buy
- TSLX Buy
- Analyst Count
- PTGX 7
- TSLX 7
- Target Price
- PTGX $52.83
- TSLX $22.43
- AVG Volume (30 Days)
- PTGX 450.1K
- TSLX 231.8K
- Earning Date
- PTGX 11-08-2024
- TSLX 11-05-2024
- Dividend Yield
- PTGX N/A
- TSLX 11.58%
- EPS Growth
- PTGX N/A
- TSLX 4.41
- EPS
- PTGX 2.75
- TSLX 2.36
- Revenue
- PTGX $319,120,000.00
- TSLX $473,575,000.00
- Revenue This Year
- PTGX $400.33
- TSLX $10.80
- Revenue Next Year
- PTGX N/A
- TSLX N/A
- P/E Ratio
- PTGX $17.54
- TSLX $8.64
- Revenue Growth
- PTGX 125.73
- TSLX 23.94
- 52 Week Low
- PTGX $13.76
- TSLX $19.33
- 52 Week High
- PTGX $48.89
- TSLX $22.35
- Technical
- Relative Strength Index (RSI)
- PTGX 60.40
- TSLX 45.10
- Support Level
- PTGX $45.33
- TSLX $20.33
- Resistance Level
- PTGX $48.89
- TSLX $20.81
- Average True Range (ATR)
- PTGX 1.28
- TSLX 0.20
- MACD
- PTGX 0.11
- TSLX -0.01
- Stochastic Oscillator
- PTGX 77.11
- TSLX 23.81
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.